Maplebear Inc. (CART)
NASDAQ: CART · Real-Time Price · USD
47.72
-0.22 (-0.46%)
At close: Aug 6, 2025, 4:00 PM
48.00
+0.28 (0.59%)
After-hours: Aug 6, 2025, 7:39 PM EDT
Achilles Therapeutics Stock Forecast
Stock Price Forecast
The 22 analysts that cover Achilles Therapeutics stock have a consensus rating of "Buy" and an average price target of $52.91, which forecasts a 10.88% increase in the stock price over the next year. The lowest target is $37 and the highest is $62.
Price Target: $52.91 (+10.88%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Achilles Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Buy | 10 | 10 | 9 | 9 | 9 | 10 |
| Hold | 11 | 11 | 11 | 11 | 11 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 27 | 26 | 26 | 25 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $54 → $55 | Strong Buy | Maintains | $54 → $55 | +15.26% | Jul 29, 2025 |
| Bernstein | Bernstein | Buy Maintains $55 → $60 | Buy | Maintains | $55 → $60 | +25.73% | Jul 21, 2025 |
| Baird | Baird | Buy Maintains $47 → $52 | Buy | Maintains | $47 → $52 | +8.97% | Jul 17, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $55 | Buy | Reiterates | $55 | +15.26% | Jun 12, 2025 |
| Jefferies | Jefferies | Hold Maintains $48 → $50 | Hold | Maintains | $48 → $50 | +4.78% | May 27, 2025 |
Financial Forecast
Revenue This Year
3.75B
from 3.38B
Increased by 11.04%
Revenue Next Year
4.10B
from 3.75B
Increased by 9.36%
EPS This Year
1.79
from 1.58
Increased by 13.17%
EPS Next Year
2.19
from 1.79
Increased by 22.70%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.9B | 4.4B | 4.7B | ||
| Avg | 3.8B | 4.1B | 4.5B | ||
| Low | 3.5B | 3.8B | 4.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.5% | 16.9% | 15.3% | ||
| Avg | 11.0% | 9.4% | 8.7% | ||
| Low | 4.8% | 2.3% | 1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 2.47 | 3.29 | 3.79 | |
| Avg | 1.79 | 2.19 | 2.60 | |
| Low | 1.37 | 1.73 | 1.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 56.1% | 83.8% | 72.7% | |
| Avg | 13.2% | 22.7% | 18.5% | |
| Low | -13.2% | -3.0% | -21.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.